Comment from Roy Castle Lung Cancer Foundation

- We have noted the Assessment Report for this appraisal and look forward to discussion at the Appraisal Committee in January. We have no additional research evidence or data to add.

- We refer to previously submitted comments from Roy Castle Lung Cancer Foundation on this appraisal and strongly support that Erlotinib continue to be available in this second line indication. As an oral, well tolerated therapy, it represents an important treatment option for lung cancer patients.

Jesme Fox